CN104411690A - 作为lpar拮抗剂的取代的吡唑化合物 - Google Patents

作为lpar拮抗剂的取代的吡唑化合物 Download PDF

Info

Publication number
CN104411690A
CN104411690A CN201380032266.8A CN201380032266A CN104411690A CN 104411690 A CN104411690 A CN 104411690A CN 201380032266 A CN201380032266 A CN 201380032266A CN 104411690 A CN104411690 A CN 104411690A
Authority
CN
China
Prior art keywords
phenyl
base
methyl
pyrazoles
cyclopropane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380032266.8A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·迪姆斯·加布里埃尔
马修·迈克尔·汉密尔顿
钱义民
阿奇尤特哈拉·西杜瑞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48656033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104411690(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN104411690A publication Critical patent/CN104411690A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380032266.8A 2012-06-20 2013-06-17 作为lpar拮抗剂的取代的吡唑化合物 Pending CN104411690A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661958P 2012-06-20 2012-06-20
US61/661,958 2012-06-20
PCT/EP2013/062458 WO2013189862A1 (en) 2012-06-20 2013-06-17 Substituted pyrazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
CN104411690A true CN104411690A (zh) 2015-03-11

Family

ID=48656033

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380032266.8A Pending CN104411690A (zh) 2012-06-20 2013-06-17 作为lpar拮抗剂的取代的吡唑化合物

Country Status (22)

Country Link
US (1) US20150259295A1 (pt-PT)
EP (1) EP2864294A1 (pt-PT)
JP (1) JP2015520201A (pt-PT)
KR (1) KR20150011003A (pt-PT)
CN (1) CN104411690A (pt-PT)
AU (1) AU2013279510A1 (pt-PT)
BR (1) BR112014031108A2 (pt-PT)
CA (1) CA2869602A1 (pt-PT)
CL (1) CL2014003242A1 (pt-PT)
CO (1) CO7160077A2 (pt-PT)
CR (1) CR20140516A (pt-PT)
EA (1) EA201492283A1 (pt-PT)
HK (1) HK1206341A1 (pt-PT)
IL (1) IL236091A0 (pt-PT)
IN (1) IN2014DN09347A (pt-PT)
MA (1) MA37765A1 (pt-PT)
MX (1) MX2014014105A (pt-PT)
PE (1) PE20142445A1 (pt-PT)
PH (1) PH12014502364A1 (pt-PT)
SG (1) SG11201407229UA (pt-PT)
UA (1) UA109867C2 (pt-PT)
WO (1) WO2013189862A1 (pt-PT)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975235B2 (en) 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
US10000459B2 (en) 2013-03-15 2018-06-19 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
RU2689315C2 (ru) 2014-06-27 2019-05-27 Убе Индастриз, Лтд. Соль гетероциклического соединения, замещенного галогеном
KR20200100712A (ko) * 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 피라졸 n-연결된 카르바모일 시클로헥실 산
JP7431961B2 (ja) 2019-11-15 2024-02-15 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニストとしてのトリアゾールカルバメートピリジルスルホンアミド及びその使用
KR20230019880A (ko) 2020-06-03 2023-02-09 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
AU2021285747A1 (en) 2020-06-03 2023-01-19 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TW202400561A (zh) * 2021-05-11 2024-01-01 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011017350A2 (en) * 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
CN102245584A (zh) * 2008-12-15 2011-11-16 艾米拉制药公司 溶血磷脂酶受体的拮抗剂
CN102459204A (zh) * 2009-06-03 2012-05-16 艾米拉医药股份有限公司 溶血磷脂酸受体的多环拮抗剂
WO2012078593A2 (en) * 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005063241A1 (ja) * 2003-12-26 2007-07-19 小野薬品工業株式会社 ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US8975235B2 (en) * 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245584A (zh) * 2008-12-15 2011-11-16 艾米拉制药公司 溶血磷脂酶受体的拮抗剂
CN102459204A (zh) * 2009-06-03 2012-05-16 艾米拉医药股份有限公司 溶血磷脂酸受体的多环拮抗剂
WO2011017350A2 (en) * 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
WO2012078593A2 (en) * 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JS SWANEY,等: "A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model", 《BRITISH JOURNAL OF PHARMACOLOGY》, vol. 160, no. 7, 31 December 2010 (2010-12-31), pages 1699 - 1713 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
WO2020147739A1 (zh) * 2019-01-15 2020-07-23 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
CN112771027A (zh) * 2019-01-15 2021-05-07 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
CN112771027B (zh) * 2019-01-15 2024-03-05 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法

Also Published As

Publication number Publication date
SG11201407229UA (en) 2014-12-30
US20150259295A1 (en) 2015-09-17
MX2014014105A (es) 2015-03-05
IL236091A0 (en) 2015-02-01
KR20150011003A (ko) 2015-01-29
EP2864294A1 (en) 2015-04-29
PH12014502364A1 (en) 2015-01-12
CL2014003242A1 (es) 2015-03-20
JP2015520201A (ja) 2015-07-16
EA201492283A1 (ru) 2015-04-30
BR112014031108A2 (pt) 2017-06-27
CA2869602A1 (en) 2013-12-27
PE20142445A1 (es) 2015-01-28
CO7160077A2 (es) 2015-01-15
UA109867C2 (ru) 2015-10-12
IN2014DN09347A (pt-PT) 2015-07-17
AU2013279510A1 (en) 2014-10-16
WO2013189862A1 (en) 2013-12-27
HK1206341A1 (en) 2016-01-08
MA37765A1 (fr) 2017-04-28
CR20140516A (es) 2014-12-01

Similar Documents

Publication Publication Date Title
CN104411690A (zh) 作为lpar拮抗剂的取代的吡唑化合物
CN104411692A (zh) 作为lpar拮抗剂的n-烷基三唑化合物
CN104395299A (zh) 作为lpar拮抗剂的n-芳基三唑化合物
TWI648273B (zh) 作為激酶抑制劑之雜環醯胺類（三）
CN101925603B (zh) 囊性纤维化跨膜通道调节因子的调节剂
CN1328247C (zh) 用作缓激肽拮抗剂的在其甲基上具有取代基的n－联苯甲基氨基环烷烃羧酰胺衍生物
CA3069226A1 (en) Methods of treatment for cystic fibrosis
CN101326175B (zh) C-met/hgfr抑制剂的多晶型物
AU2014239995B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
CN103153963B (zh) 环丙烷化合物
CN103534240B (zh) 选择性fak抑制剂
CN102781922A (zh) Tgr5激动剂
CN102781898B (zh) 使用q2拟肽的gpbp抑制
TW201808949A (zh) 化學化合物
CN103118680A (zh) 杂芳基甲酰胺
WO2016127916A1 (zh) 作为长效dpp-iv抑制剂的取代的氨基六元饱和杂脂环类
CN101304983A (zh) 作为ppar调节剂的化合物和组合物
CN105339350A (zh) 二氢吡啶酮mgat2抑制剂
US9572792B2 (en) Coumarin compounds as receptor modulators with therapeutic utility
CN109651208B (zh) N-芳基磺酰胺类化合物，其药物组合物及其用途
CN104507914A (zh) Lpar-取代的氰基吡唑化合物
CN111499591A (zh) RORγ调节剂
CN101981009B (zh) 作为hdl-胆固醇升高剂的2-三氟甲基烟酰胺衍生物
JP6199406B2 (ja) ジアシルグリセロールアシルトランスフェラーゼ阻害剤としての新規化合物
CN103153957A (zh) N-吡啶-3-基或n-吡嗪-2-基甲酰胺类

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1206341

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150311

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1206341

Country of ref document: HK